(Reuters) – British drugmaker AstraZeneca could pay up to $6 billion to Japan’s Daiichi Sankyo as part of a new collaboration to develop and market a type of potential cancer treatment for multiple tumour types.
AstraZeneca will pay Daiichi an upfront payment of $1 billion for DS-1062, a type of antibody drug conjugate (ADC).
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Saumyadeb Chakrabarty)
